Biodexa Pharmaceuticals Files 6-K Report

TL;DR

Biodexa Pharma (BDRX) filed a 6-K, standard foreign issuer report. Nothing major.

AI Summary

Biodexa Pharmaceuticals PLC filed a Form 6-K on October 15, 2024. The filing is a report of a foreign private issuer and indicates the company files annual reports under Form 20-F. The company's principal executive offices are located in Cardiff, United Kingdom.

Why It Matters

This filing provides routine updates for investors regarding Biodexa Pharmaceuticals PLC's status as a foreign private issuer and its reporting obligations.

Risk Assessment

Risk Level: low — This filing is a routine report for a foreign private issuer and does not contain significant new financial or operational information.

Key Players & Entities

• Biodexa Pharmaceuticals PLC (company) — Registrant
• October 15, 2024 (date) — Filing date
• Cardiff, United Kingdom (location) — Principal executive offices
• Form 20-F (document) — Annual report cover
• Form 6-K (document) — Report type

FAQ

Filing Documents

• w10142406k.htm (6-K) — 11KB
• ex99_1.htm (EX-99.1) — 9KB
• 0001214659-24-017559.txt ( ) — 21KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 6-K ___________________________ REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨ EXPLANATORY NOTE On October 15, 2024, Biodexa Pharmaceuticals PLC (the “Company”) issued a press release announcing the Company’s successful appeal of the Nasdaq Stock Market LLC’s delisting determination. A copy of the press release is attached hereto as Exhibit 99.1. The information included in this report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference into the registration forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SUBMITTED HEREWITH Attached to the Registrant’s Form 6-K filing for the month of October 2024 is: Exhibit No. Description 99.1 Press release dated October 15, 2024. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC Date: October 15, 2024 By: /s/ Stephen Stamp Stephen Stamp Chief Executive Officer and Chief Financial Officer 3

View Full Filing

View this 6-K filing on SEC EDGAR